Detalhe da pesquisa
1.
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
N Engl J Med
; 381(9): 803-815, 2019 08 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31339677
2.
Is laboratory screening prior to antiretroviral treatment useful in Johannesburg, South Africa? Baseline findings of a clinical trial.
BMC Public Health
; 17(Suppl 3): 445, 2017 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28832288
3.
Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens.
Open Forum Infect Dis
; 11(3): ofae007, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38529213
4.
Differential Responsiveness of the Platelet Biomarkers, Systemic CD40 Ligand, CD62P, and Platelet-Derived Growth Factor-BB, to Virally-Suppressive Antiretroviral Therapy.
Front Immunol
; 11: 594110, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33584658
5.
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Lancet HIV
; 7(10): e666-e676, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33010240
6.
Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial.
J Acquir Immune Defic Syndr
; 80(2): 224-233, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30640204
7.
Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial.
Lancet HIV
; 6(7): e428-e437, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31202690
8.
CD4 cell count variability with repeat testing in South Africa: Should reporting include both absolute counts and ranges of plausible values?
Int J STD AIDS
; 29(11): 1048-1056, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29749876
9.
Co-enrollment in multiple HIV prevention trials - experiences from the CAPRISA 004 Tenofovir gel trial.
Contemp Clin Trials
; 32(3): 333-8, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21278001
10.
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
Trials
; 12: 67, 2011 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-21385354
11.
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Science
; 329(5996): 1168-74, 2010 Sep 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-20643915